Psoriasis Vulgaris
Conditions
Keywords
Topicals, Long-term
Brief summary
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.
Interventions
DRUGAny topical drug treatment
Any treatment strategy used to prevent relapse of psoriasis symptoms
Sponsors
LEO Pharma
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients planned to receive topical treatment of any kind to prevent relapse of symptoms * Written informed consent
Exclusion criteria
* Contraindications to selected treatment * Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time of relapse | Up to 52 weeks | Length of relapse free period after start of maintenance strategy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index | Up to 52 weeks | Standard QoL measure within dermatology |
| PGA (physician's global assessment of symptoms) | Up to 52 weeks | 5-point verbal rating scale |
| PsGA (patient's global assessment of symptoms) | Up to 52 weeks | 5-point verbal rating scale |
Countries
Russia
Outcome results
None listed